Mark Lee, MD, PhD

Chief Executive Officer and Co-Founder

Dr. Lee was most recently Senior Vice President and Global Head for Personalized Healthcare, Product Development at Genentech/Roche. Prior to joining Genentech, Mark was a member of the founding leadership team and Head of Clinical Development and Medical Affairs at GRAIL, where his team built one of the largest clinical research programs in genomic medicine aimed at early cancer detection. Some of his previous roles include Lead for Oncology Clinical Sciences at Google[x] Life Sciences, Chief Medical Officer at Boreal Genomics, and Vice President of Oncology Development at Genomic Health, where he led the successful development and validation of the Oncotype DX Colon and Prostate Cancer Assays. Mark received a PhD in Biological Chemistry and Molecular Pharmacology from Harvard, and a MD from Stanford University, where he completed his internal medicine residency and medical oncology fellowship.

Christer Svedman, MD, PhD

Head of Clinical Science and Co-Founder

Christer has more than 20 years of oncology experience working in academia (Karolinska, Stockholm, Sweden), pharma (GSK) and diagnostic development (Genomic Health). His research includes the development of a transdermal drug delivery technique, a technique for sampling of interstitial fluid, a prognostic gene expression assay in renal cancer, a liquid biopsy assay, abscopal effects of stereotactic radiation therapy and reports on differences in access to new cancer drugs. He has also worked extensively with the LC-SCRUM (Japanese lung cancer group) in Precision Medicine Asia, a spin out company from the NCCHE, focused on expanding a large clinical genomic registry in lung cancer used to screen patients for clinical trials in Japan and South-East Asia.

Dan Schneider

Head, Commercial

Dan has over 20 years of experience in global marketing for both pharmaceutical and diagnostic products. Most recently, Dan was Dx Strategy Leader in the Global Product Strategy Organization at Roche responsible for defining commercial strategies for diagnostics supporting late stage oncology molecules and cell & gene therapy programs. Previously, he was the Director of Diagnostics and Personalized Medicine at Teva where he partnered with therapeutic brand teams and regional leadership to identify opportunities to introduce diagnostic and digital solutions that provided competitive or lifecycle advantages. While at Genomic Health, Dan was Sr. Director of Marketing that launched Oncotype DX in Europe and Middle East and managed country teams and a network of distributors.

Emily Luvison

Head, Compliance

Emily is a compliance leader with oversight of cybersecurity, privacy, and quality compliance programs supporting digital health products and platforms. She was most recently the Principal Cybersecurity Compliance Lead in Digital Health Technologies at Genentech/Roche where she developed the Digital Health Technologies Compliance function and launched numerous regulated software as a medical device (SaMD) products, clinical decision support tools and digital health platforms across oncology, neurology and ophthalmology therapeutic areas. Prior to Genentech, Emily was the Head of Compliance Programs at Roche Diagnostics Information Solutions, and previously served as Senior Security Risk Assurance Consultant to Ernst & Young LLP. Emily is a Certified Information Systems Auditor and was previously a HITRUST CSF Practitioner.

Maria Ferrari

Chief of Staff

Maria has over 15 years of industry experience in operations and process development. Most recently, Maria was a Senior Product Manager at Roche leading a cross-functional ctDNA Product Core Team responsible for developing a next generation liquid biopsy assay to detect early recurrence of cancer.

Prior to this, Maria was a founding member at GRAIL, leading the build-out and management of one of the largest biobanks of research clinical samples from GRAIL’s CCGA and STRIVE observational studies. Maria spent 12 years at Google in the Ads and engineering organization and was an early member of Google Life Sciences /Verily where she helped develop its clinical program and enroll the first 100 patients into Project Baseline Health Study.

Ruchika Kumar

General Counsel and Head of People

Ruchika has over 20 years of experience in the healthcare industry providing advice and counsel on biotech/pharmaceutical regulation & compliance, digital health, market access, privacy and clinical trial innovation. She is an experienced lawyer with a demonstrated history of working successfully in the biotechnology industry. Prior to joining N-Power Medicine as Head of Legal, Ruchika spent 17 years at Genentech-Roche and most recently was the Associate General Counsel there. She is a member of the New York Bar and California Bar. She serves on the board of Muso Health and OpenBiome. She has studied at premiere institutions both in India and the US and has a postgraduate degree from the University of Pennsylvania – Law School.

Thomas Bengtsson, PhD

Head, Data Science & Advanced Analytics

Thomas is a Data Science leader with over 12 years of pharmaceutical industry experience. Thomas spent 13 years at Roche/Genentech in Biostatistics. Most recently he served as Senior Director and Global Head for Imaging-Data Science at Roche’s Personalized Healthcare, Product Development organization where he led a team working to enable large-scale image analysis across oncology and develop tools to automate response assessment based on longitudinal CT- and FDG-PET scans. Prior to Roche, Thomas was a member of the Technical Staff at Bell Laboratories. He received his PhD in Statistics from the University of Missouri-Columbia.